Ogawa M
Aichi Cancer Center, Nagoya, Japan.
Gan To Kagaku Ryoho. 1996 Aug;23(9):1143-8.
In a prospective randomized trial conducted by SWOG, CHOP has shown equivalent efficacy to second and third generation combinations, while the toxic death rate by CHOP was the smallest among regimens studied. The group thus concluded that CHOP remains the best available treatment. However judging from past results it is not definitive that CHOP is standard. Many investigators therefore have studied to obtain higher efficacy than by CHOP. Regimens for higher dose intensity with the support of G-CSF, and high dose chemotherapy with the support of autologous hematopoietic stem cells, are under way and current results are reviewed.
在SWOG进行的一项前瞻性随机试验中，CHOP方案已显示出与第二代和第三代联合方案相当的疗效，而在研究的治疗方案中，CHOP方案的毒性死亡率最低。该研究小组因此得出结论，CHOP方案仍然是现有的最佳治疗方法。然而，从过去的结果来看，CHOP方案是否为标准方案尚无定论。因此，许多研究人员致力于研究比CHOP方案疗效更高的方案。目前正在进行在粒细胞集落刺激因子（G-CSF）支持下的高剂量强度方案以及在自体造血干细胞支持下的高剂量化疗方案，并对当前结果进行综述。
